Spotlight on Briquilimab in CIndU: Jasper’s Anti-CD117 Monoclonal Antibody Shows Safety and Efficacy in Phase 1b/2a Study
Jasper Therapeutics’ briquilimab, a novel antibody therapy targeting KIT (CD117), performed well in a Phase 1b/2a study of chronic inducible urticaria (CIndU).